EXPANDed studies analysis, presented by R. Estevez-Loureiro
TR reduction in patients treated for MR with MitraClip™ TEER (without additional tricuspid intervention) in the EXPANDed studies was associated with significant quality-of-life improvement and lower mortality at 1 year. MitraClip™ TEER is not indicated for the treatment of TR nor TR patients.
LEARN MORE:
Related Resources
Poster: Primary MR in the Very Elderly
TRILUMINATE Pivotal - 2-year update EuroPCR 25
bRIGHT 2-year real-world outcomes
ACC 2023: COAPT™ trial
Navitor Valve in small aortic annuli
EXPAND Study: Data overview
Data Summary PFO closure in patients > 60 Years
ESOC presentation: PFO closure in patients > 60 Years
PCR LV 2021: Navitor™ Live-in-a-box
PCR LV 2021: Navitor™ Looking ahead
TRENDING TOPICS
Poster: Primary MR in the Very Elderly
TRILUMINATE Pivotal - 2-year update EuroPCR 25
bRIGHT 2-year real-world outcomes
